Alkermes plc. revenue by segment ALKS

Annual Quarterly

Alkermes plc. splits its revenue into 7 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Vivitrol at $467.9 million, 32% of the total.

USD in millions. The percent under a figure is the change from the year before.

Line	FY 2026 Sep 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017	FY 2016 Dec 31, 2016
Revenue	1,754	1,476	1,558	1,663	1,112	1,174	1,039	1,171	1,094	903	746
Vivitrol	—	468 +2.3% share 31.7%	457 +14.2% share 29.4%	400 +5.5% share 24.1%	379 +10.4% share 34.1%	344 +10.7% share 29.3%	311 share 29.9%	—	303 +12.4% share 27.7%	269 share 29.8%	—
Aristada And Aristada Initio	—	370 +6.9% share 25.1%	346 +5.6% share 22.2%	328 +8.5% share 19.7%	302 +9.7% share 27.2%	275 +14.2% share 23.5%	241 +27.4% share 23.2%	189 +28.0% share 16.2%	148 +58.0% share 13.5%	94 share 10.4%	—
LYBALVI	—	347 +23.8% share 23.5%	280 +45.9% share 18.0%	192 +99.8% share 11.5%	96 +1068.9% share 8.6%	8 share 0.7%	—	—	—	—	—
Royalty	—	245 -30.8% share 16.6%	355 -41.0% share 22.8%	601 +173.6% share 36.1%	220 -49.7% share 19.8%	436 +19.5% share 37.2%	365 +6.2% share 35.1%	344 -12.7% share 29.3%	394 +11.7% share 36.0%	352 share 39.0%	—
Manufacturing Revenue	—	46 -61.5% share 3.1%	119 -16.2% share 7.7%	142 +26.8% share 8.6%	112 +6.4% share 10.1%	106 -11.3% share 9.0%	119 +14.2% share 11.5%	104 -21.6% share 8.9%	133 -13.0% share 12.2%	153 share 16.9%	—
License	—	—	—	—	2 -42.9% share 0.2%	4 +233.3% share 0.3%	1 -99.3% share 0.1%	146 +201.3% share 12.4%	48 +72.8% share 4.4%	28 share 3.1%	—
Research And Development	—	—	0 -84.2% share 0.0%	0 -92.7% share 0.0%	0 -74.5% share 0.0%	1 -47.6% share 0.1%	2 -96.3% share 0.2%	53 -23.3% share 4.5%	69 +852.6% share 6.3%	7 share 0.8%	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: ALKS (Nasdaq)
Fiscal year ends: December 31
Headquarters: Dublin 4, Ireland
SEC filer status: Large accelerated filer
SEC CIK: 1520262
Former names: ANTLER SCIENCE TWO PLC (until Aug 5, 2011); Antler Science Two Ltd (until Aug 2, 2011)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.